The Role of Oncostatin M in the PDAC tumor microenvironment and macroenvironment
制瘤素 M 在 PDAC 肿瘤微环境和宏观环境中的作用
基本信息
- 批准号:10314342
- 负责人:
- 金额:$ 3.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-03 至 2023-08-02
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAdenocarcinomaAtrophicBody CompositionBody Weight ChangesBody Weight decreasedCachexiaCancer ModelCardiacCardiac MyocytesCell Culture TechniquesCellsClustered Regularly Interspaced Short Palindromic RepeatsCoculture TechniquesCollagenCommunicationDataDepositionDesmoplasticDoctor of PhilosophyEchocardiographyEnvironmentExposure toFamilyFellowshipFibroblastsFibrosisFunctional disorderGrowthHarvestHeartHistologyHumanIL6ST geneImageImmunophenotypingImplantIn VitroIndianaInflammationInflammatoryInstitutionInterleukin-6Knockout MiceLIF geneMalignant NeoplasmsMalignant neoplasm of pancreasModelingMolecular AnalysisMorphologyMusMuscleMuscle functionMuscular AtrophyMyocardial dysfunctionMyocardiumNatureOSMR geneOralOrganPancreasPancreatic AdenocarcinomaPancreatic Ductal AdenocarcinomaPatientsPhenotypePlasmaProductionProtein AnalysisPublishingRNARefractoryRegulationResearchResearch PersonnelResistanceResourcesRoleSignal TransductionSourceStromal CellsStromal NeoplasmTestingTissuesTo specifyTrainingUniversitiesWild Type MouseWorkcancer cachexiacardiac cachexiacytokinefat wastingheart functionmacrophagemedical schoolsmembermortalitymouse modelneoplastic cellneutralizing antibodyoncostatin Mpancreatic cancer cellspancreatic cancer modelreceptorresponsesingle cell sequencingskeletal muscle wastingskillstumortumor growthtumor microenvironmentwasting
项目摘要
Project Summary/Abstract
Pancreatic adenocarcinoma (PDAC) carries a 90% 5-year mortality due to the treatment refractory, highly
metastatic nature of the tumor and frequent, severe cachexia or unintentional weight loss induced by tumor.
Tumor cells interact with host cells locally to specify a highly desmoplastic microenvironment, but also induce
systemic changes in the macroenvironment, including wasting of fat and muscle. Inflammatory cytokines, such
as members of the Interleukin-6/GP130 family including IL-6 and LIF, contribute to both the microenvironment
and macroenvironment in PDAC. IL-6 and LIF promote tumor inflammation and progression, and both have been
implicated in cachexia. However, less is known about the other IL-6 family of cytokines, including Oncostatin M
(OSM). Preliminary studies support a central role for OSM in PDAC. OSM and its receptor, OSMR, are expressed
in human and murine tumors. High tumor expression of OSMR correlates with poor survival for PDAC patients.
OSM was elevated in plasma of mice with PDAC tumors. In vitro, OSM increased expression of OSMR in human
and murine tumor cells and stromal cells demonstrating feed-forward regulation. OSM induced compaction of
tumor spheroids in tumor cell/fibroblast co-cultures. In contrast, deletion of OSM but not OSMR, from hosts
decreased collagen deposition in the tumor microenvironment. While skeletal muscle wasting, was unaffected,
deletion of OSM/OSMR from the host accelerated cardiac wasting and cardiac dysfunction and reduced overall
activity in mice with PDAC tumors. These data demonstrate that OSM/OSMR signaling modulates both the tumor
microenvironment and macroenvironment in PDAC. Here we will test the following hypotheses in two Aims: 1)
OSM signaling on tumor cells through fibroblasts promotes the desmoplastic phenotype in PDAC. 2) OSM
signaling in the heart is protective of cardiac mass and function in PDAC cachexia. For AIM 1, Osm signaling
will be manipulated in monoculture and co-cultures studies using human and murine tumor and fibroblast cells;
mice deleted for OSM or OSMR will be orthotopically implanted with pancreatic cancer cells; tumor cells deleted
for OSMR will be implanted in wildtype mice; all will be evaluated by cell and molecular analysis. For AIM 2,
OSM and OSMR knockout mice will be implanted with PDAC tumor cells and evaluated for body weight change,
body composition, strength/function, cardiac function, and organ wasting. Muscle and heart will be harvested for
histomorphometry and molecular analysis. The training plan will provide the applicant with skills in CRISPR,
single cell sequencing, interpretation of omics data, immunophenotyping of tissues, cancer modeling, cardiac
dysfunction and oral and written communication. Training will take place at Indiana University School of
Medicine, a highly collaborative and resourced institution, under the direct advisement of Dr. Teresa Zimmers, a
well-published cancer cachexia researcher. Summarily, the trainee will grow as an independent investigator
within the training environment.
项目摘要/摘要
胰腺癌(PDAC)由于治疗难治,5年内死亡率高达90%。
肿瘤的转移性,以及肿瘤引起的频繁、严重的恶病质或无意中的体重减轻。
肿瘤细胞与宿主细胞局部相互作用,以指定高度促促结缔组织生长的微环境,但也诱导
宏观环境的系统性变化,包括脂肪和肌肉的浪费。炎性细胞因子,如
作为IL-6/gp130家族的成员,包括IL-6和LIF,对微环境有贡献
以及PDAC中的宏观环境。IL-6和LIF促进肿瘤炎症和进展,两者都
与恶病质有关。然而,对另一个IL-6细胞因子家族,包括肿瘤抑素M,人们知之甚少
(OSM)。初步研究支持OSM在PDAC中发挥核心作用。表达了OSM及其受体OSMR
在人类和小鼠肿瘤中。OSMR在肿瘤中的高表达与PDAC患者的生存不良有关。
PDAC瘤小鼠血浆中OSM水平升高。OSM在体外增加人OSMR的表达
小鼠肿瘤细胞和基质细胞表现出前馈调节。OSM诱导的压实
肿瘤细胞/成纤维细胞共培养中的肿瘤球体。相反,从主机中删除OSM,但不删除OSMR
减少肿瘤微环境中的胶原沉积。虽然骨骼肌萎缩,但没有受到影响,
从宿主中删除OSM/OSMR会加速心脏损耗和心功能障碍,并总体上减少
对PDAC肿瘤小鼠的活动性。这些数据表明,OSM/OSMR信号调节肿瘤
PDAC的微观环境和宏观环境。在这里,我们将在两个目标上检验以下假设:1)
肿瘤细胞上的OSM信号通过成纤维细胞促进了PDAC的促结缔组织生长表型。2)OSM
心脏中的信号对PDAC恶病质患者的心脏质量和功能具有保护作用。对于AIM 1,OSM信令
将在使用人类和小鼠肿瘤和成纤维细胞的单一培养和联合培养研究中进行操纵;
OSM或OSMR基因缺失的小鼠将被原位移植胰腺癌细胞;肿瘤细胞被删除
因为OSMR将被植入野生型小鼠体内;所有这些都将通过细胞和分子分析进行评估。对于AIM 2,
OSM和OSMR基因敲除小鼠将被植入PDAC肿瘤细胞,并评估体重变化,
身体成分、力量/功能、心脏功能和器官损耗。肌肉和心脏将被收获
组织形态计量学和分子分析。培训计划将为申请者提供CRISPR方面的技能,
单细胞测序、组学数据解释、组织免疫表型、癌症模型、心脏
功能障碍和口头和书面交流。培训将在印第安纳大学学院进行
医学,一个高度合作和资源丰富的机构,在特蕾莎·齐默斯博士的直接建议下,
著名癌症恶病质研究人员。简而言之,实习生将成长为一名独立调查员
在培训环境中。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Daenique Jengelley其他文献
Daenique Jengelley的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
- 批准号:30840003
- 批准年份:2008
- 资助金额:12.0 万元
- 项目类别:专项基金项目
相似海外基金
Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
- 批准号:
478914 - 财政年份:2023
- 资助金额:
$ 3.03万 - 项目类别:
Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
- 批准号:
23K14913 - 财政年份:2023
- 资助金额:
$ 3.03万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
- 批准号:
23K15035 - 财政年份:2023
- 资助金额:
$ 3.03万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
- 批准号:
10657069 - 财政年份:2023
- 资助金额:
$ 3.03万 - 项目类别:
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
- 批准号:
10442874 - 财政年份:2023
- 资助金额:
$ 3.03万 - 项目类别:
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
- 批准号:
23H02698 - 财政年份:2023
- 资助金额:
$ 3.03万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
- 批准号:
23K08326 - 财政年份:2023
- 资助金额:
$ 3.03万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
- 批准号:
23K14614 - 财政年份:2023
- 资助金额:
$ 3.03万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
- 批准号:
23K15075 - 财政年份:2023
- 资助金额:
$ 3.03万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
- 批准号:
10743611 - 财政年份:2023
- 资助金额:
$ 3.03万 - 项目类别: